MedTrace Logo

VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer

NCT00431704 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2023-03-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the activity and safety of the combination of vinorelbine, carboplatin and trastuzumab in HER2-positive metastatic breast cancer.

Conditions

Interventions

DRUG

vinorelbine

25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients

DRUG

carboplatin

AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients

DRUG

trastuzumab

8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression

Sponsors & Collaborators

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • Andrea De Matteis, M.D. · NCI Naples, Division of Medical Oncology C

  • Francesco Perrone, M.D., Ph.D. · NCI Naples, Clinical Trials Unit

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00431704 on ClinicalTrials.gov